Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2017 | 12-2006 | 12-2005 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 9,976 | N/A | N/A | N/A |
| TOTAL | $10,528 | $N/A | $N/A | $N/A |
| Non-Current Assets | ||||
| PPE Net | 1,316 | N/A | N/A | N/A |
| Other Non-Current Assets | 3,803 | 0 | 0 | 0 |
| TOTAL | $5,119 | $N/A | $N/A | $N/A |
| Total Assets | $15,647 | $N/A | $N/A | $N/A |
| Liabilities | ||||
| Current Liabilities | ||||
| Short Term Debt | 1,522 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 3,518 | 0 | 0 | 0 |
| Accrued Expenses | 2,112 | N/A | N/A | N/A |
| TOTAL | $17,926 | $N/A | $N/A | $N/A |
| Non-Current Liabilities | ||||
| Other Non-Current Liabilities | 3,324 | 0 | 0 | 0 |
| TOTAL | $3,324 | $N/A | $N/A | $N/A |
| Total Liabilities | $21,250 | $N/A | $N/A | $N/A |
| Shareholders' Equity | ||||
| Retained earnings | -63,787 | N/A | N/A | N/A |
| Other shareholders' equity | 53,174 | 0 | 0 | 0 |
| TOTAL | $-5,603 | $N/A | $N/A | $N/A |
| Total Liabilities And Equity | $15,647 | $0 | $0 | $0 |